Novel Synthetic Lipopeptides as Potential Mucosal Adjuvants Enhanced SARS-CoV-2 rRBD-Induced Immune Response

• DOI: 10.3389/fimmu.2022.833418
• Publication Date: 2022-03-09T08:48:55Z
• Authors: Ling Mao; Chang Liu; Jing-Yi Liu; Zi-Li Jin; Zhe Jin; Ruo-Yi Xue; Rang Feng; Guo-Cheng Li; Yan Deng; Hao Cheng; Quan-Ming Zou; Hai-Bo Li
• Keywords: 0301 basic medicine; COVID-19 Vaccines; SARS-CoV-2; structure-activity relationship; Immunology; Immunity; COVID-19; vaccine adjuvant; RC581-607; Toll-Like Receptor 2; 3. Good health; Lipopeptides; 03 medical and health sciences; Adjuvants, Immunologic; lipopeptide; Immunoglobulin G; Humans; support vector machine; Immunologic diseases. Allergy; SARS-CoV-2 rRBD; Adjuvants, Pharmaceutic

As TLR2 agonists, several lipopeptides had been proved to be candidate vaccine adjuvants. In our previous study, lipopeptides mimicking N-terminal structures of the bacterial lipoproteins were also able to promote antigen-specific immune response. However, the structure-activity relationship of lipopeptides as TLR2 agonists is still unclear. Here, 23 synthetic lipopeptides with the same lipid moiety but different peptide sequences were synthesized, and their TLR2 activities in vitro and mucosal adjuvant effects to OVA were evaluated. LP1-14, LP1-30, LP1-34 and LP2-2 exhibited significantly lower cytotoxicity and stronger TLR2 activity compared with Pam2CSK4, the latter being one of the most potent TLR2 agonists. LP1-34 and LP2-2 assisted OVA to induce more profound specific IgG in sera or sIgA in BALF than Pam2CSK4. Furthermore, the possibility of LP1-34, LP2-2 and Pam2CSK4 as the mucosal adjuvant for the SARS-CoV-2 recombinant RBD (rRBD) was investigated. Intranasally immunized with rRBD plus either the novel lipopeptide or Pam2CSK4 significantly increased the levels of specific serum and respiratory mucosal IgG and IgA, while rRBD alone failed to induce specific immune response due to its low immunogenicity. The novel lipopeptides, especially LP2-2, significantly increased levels of rRBD-induced SARS-CoV-2 neutralizing antibody in sera, BALF and nasal wash. Finally, Support vector machine (SVM) results suggested that charged residues in lipopeptides might be beneficial to the agonist activity, while lipophilic residues might adversely affect the agonistic activity. Figuring out the relationship between peptide sequence in the lipopeptide and its TLR2 activity may lay the foundation for the rational design of novel lipopeptide adjuvant for COVID-19 vaccine.